|
|
PRESS RELEASE
Transgene to Present its ImmunoOncology
Expertise at Upcoming Scientific Conferences
Strasbourg, France, March 2, 2021, 8:00 am CET – Transgene Euronext Paris: TNG, a biotech
company that designs and develops virusbased immunotherapeutics against cancer, today
announces that members of Transgene’s management and scientific team have been invited to
participate at upcoming... Lire le communiqué |
|
| |
|
| |
|
|
PRESS RELEASE
First Head & Neck Cancer Patient Treated in France
in a Phase I trial with TG4050 myvac® Platform,
Transgene’s Innovative Individualized Immunotherapy
Strasbourg, France, January 21, 2021, 07:30 am CET – Transgene Euronext Paris: TNG, a biotech
company that designs and develops virusbased immunotherapeutics against cancer, today announces
that a first patient with head... Lire le communiqué |
|
| |
|
| |
|
|
COMMUNIQUÉ DE PRESSE
Premier patient traité en France avec l’immunothérapie
individualisée TG4050 plateforme myvac® de Transgene
dans un essai clinique de Phase I cancers de la tête et du cou
Strasbourg, France, le 21 janvier 2021, 07h30 – Transgene Euronext Paris : TNG, société de
biotechnologie qui conçoit et développe des immunothérapies du cancer reposant sur des vecteurs... Lire le communiqué |
|
| |
|
| |
|
|
Transgene and Hypertrust Patient Data Care announce successful
golive of the world’s first blockchain solution
for clinical trials of personalized healthcare
Strasbourg FR / Munich DE – July 9, 2020 – 8:30 am CET Transgene and Hypertrust Patient Data
Care today announced as a world premiere the first productive blockchain solution for clinical trials... Lire le communiqué |
|
| |
|
| |
|
|
Transgene présente des nouvelles données très encourageantes,
issues de ses deux plateformes innovantes,
au congrès de l’AACR 2020
Strasbourg, France, le 22 juin 2020, 15h15 – Transgene Euronext Paris : TNG, société de biotechnologie
qui conçoit et développe des immunothérapies du cancer reposant sur des vecteurs viraux, présente la
diversité de... Lire le communiqué |
|
| |
|
| |
|
|
Transgene’s and BioInvent’s BT001 achieves outstanding tumor
cure rates in preclinical models
✓ Proof of concept for novel oncolytic virus with differentiated antiCTLA4 antibody
✓ Significant antitumor activity of BT001 seen in several immunocompetent models
✓ Treatment with BT001 also induced a specific and longlasting immune memory, which is
thought... Lire le communiqué |
|
| |
|
| |
|
|
Transgene et BioInvent obtiennent des taux exceptionnels
d’élimination de tumeurs dans plusieurs modèles précliniques
évaluant BT001
✓ Preuve de concept d’un nouveau virus oncolytique encodant un anticorps antiCTLA4
✓ Une activité antitumorale significative de BT001 est observée dans plusieurs modèles
tumoraux de souris immunocompétentes
... Lire le communiqué |
|
| |
|
| |
